`U.S. Patent No. 8,664,231
`
`
`
`
`
`Attorney Docket No.
`110670-0010-651
`
`Patent Owner’s Updated Exhibit List – November 22, 2016
`
`January 8, 2016 Letter from Jason Greer to Terri Shoemaker re
`Rasuvo™ and Orange Book-Listed U.S. Patent No. 8,664,231
`WA Secretary of State Registration Detail for Frontier Therapeutics,
`LLC, available at
`http://www.sos.wa.gov/corps/search_detail.aspx?ubi=603566537
`WA Secretary of State Registration Detail for Jason Paul Greer
`Enterprises LLC, available at
`http://www.sos.wa.gov/corps/search_detail.aspx?ubi=603185788
`State of Washington Business Licensing Service entry for Jason Paul
`Greer Enterprises Limited Liability Company, available at
`http://bls.dor.wa.gov/LicenseSearch/lqsLicenseDetail.aspx?RefID=1084
`904, last visited May 24, 2016
`Whois Data for Frontiertherapeuticsnw.com, available at
`http://www.whoismind.com/whois/frontiertherapeuticsnw.com.html, last
`visited June 1, 2016
`Declaration of Dr. Michael E. Weinblatt, dated June 17 2014
`Redline comparison of Gershwin Declaration and Weinblatt Declaration
`“Gershwin” and “Methotrexate” publications list, NCBI.com, available
`at https://www.ncbi.nlm.nih.gov/pubmed, last visited May 22, 2016
`Andrea T. Borchers et al., “The Use of Methotrexate in Rheumatoid
`Arthritis,” Seminars in Arthritis and Rheumatism, Vol. 34, No. 1 (Aug.
`2004)
`Jiří Grim et al., “Pharmacokinetics and Pharmacodynamics of
`Methotrexate in Non-Neoplastic Diseases,” Special Populations (2003)
`Drugs@FDA: FDA Approved Drug Products (Mexate), available at
`http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseac
`tion=Search.DrugDetails, last visited May 22, 2016
`Bingham SJ et al. “Parenteral methotrexate should be given before
`biological therapy,” Rheumatology, 2003, vol. 42: 1009-1010
`U.S. Patent No. 8,480,631
`Breslin, et al., “Improving Tolerance and Bioavailability of
`Methotrexate by Switching from Oral to Subcutaneous Route of
`Administration,” Rheumatology 388 (2005)
`Balis, et al., “Pharmacokinetics of Subcutaneous Methotrexate,” Journal
`of Clinical Oncology 6(12):1882-1886 (1988)
`
`2001
`
`2002
`
`2003
`
`2004
`
`2005
`
`2006
`2007
`2008
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`2014
`
`2015
`
`
`
`
`
`
`
`2016
`
`2017
`
`2018
`2019
`
`2020
`
`2021
`
`2022
`
`2023
`2024
`
`2025
`
`2026
`2027
`
`2028
`
`2029
`
`2030
`
`2031
`
`2032
`2033
`
`
`
`Schiff, et al., “Head-to-head, randomized, crossover study of oral versus
`subcutaneous methotrexate in patients with rheumatoid arthritis,” Ann
`Rheum Dis 0:1-3 (2014)
`Antares Pharma Press Release, “Antares Pharma Announces the
`Publication of a Head-to-Head, Randomized, Crossover Study of Oral
`versus Subcutaneous Methotrexate in Patients with Rheumatoid
`Arthritis,” Business Wire (Apr. 17, 2014)
`Expert Declaration of Elena Massarotti, MD., dated Nov. 14, 2014
`Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 7th
`Ed, 1985
`2007 CDC Guidelines for Isolation Precautions: Preventing
`Transmission of Infectious Agents in Healthcare Settings
`SICOR Pharmaceuticals ANDA Suitability Petition Methotrexate
`Injection, USP (100mb/mL), dated April 28, 2006
`Brazaeu et al. “Current Perspectives on Pain Upon Injection of Drugs,”
`J. Pharm. Sci., 1998, vol. 87(6):667-677
`Day 75 Response Report
`Chapter 3: Drug Administration, Drug Therapy In Nursing, 3rd Ed.,
`Aschenbrenner DS and Venable SJ, Wolters Kluwer Health (2009)
`Chapter 16: Human: Veterinary Technology Cross Over, Long Acting
`Animal Health Drug Products: Fundamentals and Applications, Baird et
`al., Springer (2013)
`Drugs@FDA Summary Table
`Drugs@FDA Search Results for “Methotrexate,” available
`at
`http:///www.accessdata.fda.gov/scripts/cder/drugsatfda/inde
`x.cfm
`Kurnick D. et al., “Bioavailability of oral vs. subcutaneous low-dose
`methotrexate in patients with Crohn’s disease,” Aliment. Pharmacol.
`Ther., 2003, vol. 18:57-63
`Pavy S. et al., “Methotrexate therapy for rheumatoid arthritis: clinical
`practice guidelines based on published evidence and expert opinion,”
`Joint Bone Spine, 2006, vol. 73:388-395
`Declaration of Maria Salgado in Support of Patent Owner’s Preliminary
`Response
`Declaration of Michael P. Duffey in Support of Patent Owner’s
`Preliminary Response
`Expert Declaration of Dr. Sean Nicholson
`MTX Information with Strength (MEDAC-NJ 0002040)
`
`-2-
`
`
`
`
`
`2034
`
`2035
`
`2036
`
`2037
`
`2038
`
`2039
`
`2040
`
`2041
`
`2042
`
`2043
`
`2044
`
`2045
`
`2046
`
`2047
`
`
`
`Ashburn, T. et al., “Drug Repositioning: Identifying and Developing
`New Uses for Existing Drugs,” Nature Reviews Drug Discovery, Vol.
`3, No. 8, pp. 673-683 (2004)
`Augustin, M. et al., “Adherence in the Treatment of Psoriasis: A
`Systematic Review,” Dermatology, Vol. 222, pp. 363-374 (2011)
`Bemt, B., et al., “Medication Adherence in Patients With Rheumatoid
`Arthritis: A Critical Appraisal of the Existing Literature,” Expert
`Review of Clinical Immunology, Vol. 8, No. 4, pp. 337-351 (2012)
`Beyer, V. et al., “Recent Trends in Systemic Psoriasis Treatment
`Costs,” Archives of Dermatology, Vol. 146, No. 1, pp. 46-54 (2010)
`Goutsou, M. et al., “Biologics Utilization for Rheumatoid Arthritis in the
`United States: An Observational Longitudinal Study,” Journal of
`Medical Marketing, Vol. 13, No. 2, pp. 74-81 (2013)
`Gowdie, P., “Review of Disease - Modifying Anti Rheumatic Drugs in
`Paediatric Rheumatic Disease,” 18th Expert Committee on the
`Selection and Use of Essential Medicines (2010)
`Greenapple, R., “Trends in Biologic Therapies for Rheumatoid
`Arthritis: Results from a Survey of Payers and Providers,” American
`Health & Drug Benefits, Vol. 5, No. 2, pp. 83-92 (2012)
`Helmick, C. et al., “Estimates of the Prevalence of Arthritis and Other
`Rheumatic Conditions in the United States,” Arthritis and Rheumatism,
`Vol. 58, No. 1, pp. 15-25 (2008)
`Kalb, R. et al., “Methotrexate and Psoriasis: 2009 National Psoriasis
`Foundation Consensus Conference,” Journal of American Academy of
`Dermatology, Vol. 60, No. 5, pp. 824-837 (2009)
`Kurd, S. et al., “The Prevalence of Previously Diagnosed and Undiagnosed
`Psoriasis in US Adults,” Journal of the American Academy of
`Dermatology, Vol. 60, Issue 2, pp. 218-224 (2009)
`Menter, A. et al., “Guidelines of Care for the Management of Psoriasis
`and Psoriatic Arthritis: Section 4,” Journal of the American Academy of
`Dermatology, Vol. 61, No. 3, pp. 451-485 (2009)
`Michaud, K. et al., “Direct Medical Costs and Their Predictors in Patients
`with Rheumatoid Arthritis,” Arthritis & Rheumatism, Vol. 48, No. 10,
`pp. 2750-2762 (2003)
`Mount, C. et al., “Rheumatoid Arthritis Market,” Nature Reviews Drug
`Discovery, Vol. 4, pp. 11-12 (2005)
`Paul, S. et al., “How to Improve R&D Productivity: The Pharmaceutical
`Industry’s Grand Challenge,” Nature Reviews Drug Discovery, Vol. 9,
`No. 3, pp. 203-214 (2010)
`
`-3-
`
`
`
`
`
`2048
`
`2049
`
`2050
`
`2051
`
`2052
`
`2053
`
`2054
`
`2055
`2056
`
`2057
`
`2058
`
`Rachakonda, T. et al., “Psoriasis Prevalence Among Adults in the United
`States,” Journal of the American Academy of Dermatology, Vol. 70,
`No. 3, pp. 512-516 (2014)
`Saag, K. et al., “American College of Rheumatology 2008
`Recommendations for the Use of Nonbiologic and Biologic Disease-
`Modifying Antirheumatic Drugs in Rheumatoid Arthritis,” Arthritis &
`Rheumatism (Arthritis Care & Research), Vol. 59, No. 6, pp. 762-784
`(2008)
`Smith, K., “Systemic Therapy of Psoriasis Using Methotrexate,” Skin
`Therapy Letter, Vol. 6, No. 3, pp. 1-5 (2000)
`Steinwachs, D., “Pharmacy Benefit Plans and Prescription Drug
`Spending,” Journal of the American Medical Association, Vol. 288, No.
`14, pp. 1773-1774 (2002)
`DiMasi, J. et al., “R&D Costs and Returns to New Drug Development:
`A Review of the Evidence,” in P. Danzon, and S. Nicholson (eds), The
`Oxford Handbook of The Economics of the Biopharmaceutical Industry,
`Oxford University Press, pp. 21-46 (2012)
`Eisenberg, R., “Patents and Regulatory Exclusivity,” in P. Danzon, and
`S. Nicholson (eds), The Oxford Handbook of The Economics of the
`Biopharmaceutical Industry, Oxford University Press, pp. 167-198
`(2012)
`Malani, A. et al., “The Regulations of Medical Products,” in P. Danzon,
`and S. Nicholson (eds), The Oxford Handbook of the Economics of the
`Biopharmaceutical Industry, Oxford University Press, pp. 100-142
`(2012)
`Omitted
`“October 2006 ASP Pricing File - Updated 12/19/07,” Centers for
`Medicare and Medicaid Services,
`http://www.cms.gov/apps/ama/license.asp?file=/McrPartBDrugAvgSalesP
`rice/downloads /oct06asphcpcs.zip
`“October 2014 ASP Pricing File 09/12/14,” Centers for Medicare and
`Medicaid Services,
`http://www.cms.gov/apps/ama/license.asp?file=/McrPartBDrugAvgSalesPri
`ce/downloads /2014-October-ASP-Pricing-File.zip
`Declaration of Brian Gummow in Support of Patent Owner’s Preliminary
`Response
`
`
`
`-4-
`
`
`
`
`
`2059
`
`2060
`
`2061
`
`2062
`
`2063
`
`2064
`
`2065
`
`2066
`
`2067
`
`2068
`
`2069
`
`2070
`
`
`
`“Antares Pharma Announces Availability of Otrexup™ (Methotrexate)
`Injection for Subcutaneous Use to Treat Rheumatoid Arthritis (RA) and
`psoriasis in adults, and polyarticular idiopathic arthritis (pJIA) in
`Children,” Antares Pharma Press Release, dated Jan. 15, 2014
`“Supply of a Cancer Drug May Run Out Within Weeks,” New York
`Times, dated Feb. 10, 2012
`“About Rasuvo™,” Medac Pharma,
`http://www.rasuvo.com/patients/background
`“Antares Pharma’s (ATRS) CEO Paul Wotton on Q1 2014 Results -
`Earnings Call Transcript,” Seeking Alpha, May 9, 2014,
`http://seekingalpha.com/article/2206743-antarespharmas-atrs-ceo-paul-
`wotton-on-q1-2014-results-earnings-call-transcript?part=single
`“Antares: Thoughts on the Upcoming Otrexup™ Launch,” Seeking Alpha,
`Nov, 8, 2013, http://seekingalpha.com/article/1822102-antares-thoughts-
`on-the-upcoming-otrexuplaunch
`“Antares; My View of How Otrexup™ and Medac's New Product
`Rasuvo™ May Compete (ATRS, Buy, $2.54),” SmithOnStocks, July
`12, 2014, http.//smithonstocks.com/antares-my-view-of-how-otrexup-and-
`medacs-new-productrasuvo-may-compete-atrs-buy-2-54/
`“Arthritis Today Drug Guide,” Arthritis Foundation,
`http://www.arthritistoday.org/arthritis-treatment/medications/drug-
`guide/search-byclass.php?drugclass=DMARDs
`“DMARDs for Juvenile Idiopathic Arthritis: A Review of the Research
`for Parents and Caregivers,” John M Eisenberg Center for Clinical
`Decisions and Communications Science, Baylor College of Medicine,
`Sept. 26, 2011,
`http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0016454/
`“Drug Guide: DMARDs,” Arthritis Foundation,
`http://www.arthritistoday.org/arthritis-treatment/medications/types-of-
`drugs/disease-modifying-drugs/drug-guide-dmards.php
`“FDA Approval Letter: Otrexup™,” Drugs@FDA, Oct. 11, 2013,
`http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204824Orig2s
`000Approv.pdf
`“FDA Approval Letter: Rasuvo™,” Drugs@FDA, July 10, 2014,
`http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205776Orig1s
`000Approv.pdf
`“FDA OKs a New Methotrexate Injection Device,” Arthritis
`Foundation, Aug. 15, 2014, http://www.arthritistoday.org/news/new-
`methotrexate-autoinjector-349.php
`
`-5-
`
`
`
`
`
`2071
`
`2072
`
`2073
`
`2074
`
`2075
`
`2076
`
`2077
`
`2078
`
`"FDA Summary Review: Otrexup™," Drugs@FDA, Oct. 15,
`2013,
`http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204824Orig1s
`000Admincorres.pdf
`“Frequently Asked Questions on Prescription Drug User Fees
`(PDUFA),” U.S. Food and Drug Administration,
`http://www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusines
`sAssistance/ucm069943.htm
`“Guidance for Industry: Applications Covered by Section
`505(b)(2),”U.S. Food and Drug Administration, Oct. 1999,
`http://www.fda.gov/downloads/Drugs/.../Guidances/ucm079345.pdf
`“Highlights of Prescribing Information: OXTREXUP™,”
`Drugs@FDA, Nov. 2014,
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204824s003l
`bl.pdf
`
`“Highlights of Prescribing Information: RASUVO™,”
`Drugs@FDA, July 2014,
`https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205776s00
`0lbl.pdf
`“How Medicare Prescription Drug Plans and Medicare Advantage
`Plans with Prescription Drug Coverage (MA-PDs) Use Pharmacies,
`Formularies, & Common Coverage Rules,” Department of Health &
`Human Services, October 2015,
`https://www.medicare.gov/Publications/Pubs/pdf/11136.pdf
`“Jefferies Boosts PT on Antares Pharma (ATRS) 20% into
`OTREXUP™ PDUFA; Maintains Buy,” StreetInsiden.com, Oct. 8,
`2013,
`http://www.streetinsider.com/Analyst+Comments/Jefferies+Boosts+PT
`+on+Antares+Pharma+%28ATRS%29+20%25+into+OTREXUP+PDU
`FA%3B+Maintains+Buy/8758127.html
`“Juvenile Idiopathic Arthritis (JIA),” NYU Langone Medical Center
`Division of Pediatric Rheumatology,
`http://pediatrics.med.nyu.edu/rheumatology/patient-care/juvenile-
`idiopathic-arthritis-jia
`
`
`
`-6-
`
`
`
`
`
`2079
`
`2080
`
`2081
`
`2082
`
`2083
`
`2084
`
`2085
`
`2086
`2087
`2088
`2089
`2090
`
`
`“Memorandum Report: Comparison of First-Quarter 2012 Average Sales
`Prices and Average Manufacturer Prices: Impact on Medicare
`Reimbursement for Third Quarter 2012, OEI-03-12-00730,”
`Department of Health and Human Services, Dec. 12, 2012,
`https://oig.hhs.gov/oei/reports/oei-03-12-00730.pdf
`“Methotrexate Fact Sheet,” American College of Rheumatology,
`May 2012,
`https://www.rheumatology.org/practice/clinical/patients/medications/meth
`otrexate.pdf
`“Prescription Drug Trends,” Kaiser Family Foundation, Fact Sheet
`#3057-30, Oct. 2004,
`http://www.cigna.com/pdf/Prescription-Drug-Trends-Oct2004.pdf
`“Psoriasis Treatments with Next Generation Vitamin D Analogs,”
`Wisconsin Alumni Research Foundation, http://www.warf.org/for-
`industry/vitamin-d/psoriasis/psoriasis.cmsx
`“Questions and Answers about Juvenile Arthritis,” National
`Institute of Arthritis and Musculoskeletal and Skin Diseases, Aug.
`2013, http://www.niams.nih.gov/Health Info/Juv Arthritis/#1
`“Rheumatoid Arthritis Signs and Symptoms,” Johns Hopkins
`Arthritis Center, http://www.hopkinsarthritis.org/arthritis-
`info/rheumatoid-arthritis/ra-symptoms/
`“State and County QuickFacts,” United States Census
`Bureau, http://quickfacts.census.gov/qfd/states/00000.html
`FDA Orange Book Data File Patent.txt
`FDA Orange Book Data File Products.txt
`FDA Orange Book Data File Exclusivity.txt
`Compilation of Drug Labels
`Settlement Agreement [Confidential]
`
`
`
`-7-